Screener
Amphastar Pharmaceuticals AMPH Net debt / EBITDA
Net debt / EBITDA at other companies
Other financials
Where this comes from
Calculated from Amphastar Pharmaceuticals’s reported figures.
Based on the most recent quarter.
The source filing: Amphastar Pharmaceuticals’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:50 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001297184-26-000047
FAQ
- What is Amphastar Pharmaceuticals's net debt / EBITDA?
- Amphastar Pharmaceuticals (AMPH) reported net debt / EBITDA of 2.7× in Q2 2026.
- How has Amphastar Pharmaceuticals's net debt / EBITDA changed year-over-year?
- Amphastar Pharmaceuticals's net debt / EBITDA increased by 37.1% year-over-year, from 2× to 2.7×.
- What is the long-term trend for Amphastar Pharmaceuticals's net debt / EBITDA?
- Over 5 years (2020 to 2025), Amphastar Pharmaceuticals's net debt / EBITDA has grown at a 26.4% compound annual growth rate (CAGR), from -0.8× to 2.5×.
- What does net debt / EBITDA mean?
- Net debt (total debt minus cash) divided by trailing-twelve-month EBITDA. Expresses leverage in years — roughly how long it would take to repay net debt out of operating cash earnings.
Ask your AI about Amphastar Pharmaceuticals's net debt / ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude